292 related articles for article (PubMed ID: 31981965)
21. Structure-based screening and molecular dynamics simulations offer novel natural compounds as potential inhibitors of Mycobacterium tuberculosis isocitrate lyase.
Shukla R; Shukla H; Sonkar A; Pandey T; Tripathi T
J Biomol Struct Dyn; 2018 Jun; 36(8):2045-2057. PubMed ID: 28605994
[TBL] [Abstract][Full Text] [Related]
22. New synergistic benzoquinone scaffolds as inhibitors of mycobacterial cytochrome bc1 complex to treat multi-drug resistant tuberculosis.
Chilamakuru NB; Vn AD; G VB; Pallaprolu N; Dande A; Nair D; Pemmadi RV; Reddy Y P; Peraman R
Eur J Med Chem; 2024 Jun; 272():116479. PubMed ID: 38733886
[TBL] [Abstract][Full Text] [Related]
23. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
[TBL] [Abstract][Full Text] [Related]
24. Substrate and reaction specificity of Mycobacterium tuberculosis cytochrome P450 CYP121: insights from biochemical studies and crystal structures.
Fonvielle M; Le Du MH; Lequin O; Lecoq A; Jacquet M; Thai R; Dubois S; Grach G; Gondry M; Belin P
J Biol Chem; 2013 Jun; 288(24):17347-59. PubMed ID: 23620594
[TBL] [Abstract][Full Text] [Related]
25. Pharmacoinformatics-based identification of anti-bacterial catalase-peroxidase enzyme inhibitors.
Jangam CS; Bhowmick S; Chorge RD; Bharatrao LD; Patil PC; Chikhale RV; AlFaris NA; ALTamimi JZ; Wabaidur SM; Islam MA
Comput Biol Chem; 2019 Dec; 83():107136. PubMed ID: 31630014
[TBL] [Abstract][Full Text] [Related]
26. High-throughput virtual screening, ADME analysis, and estimation of MM/GBSA binding-free energies of azoles as potential inhibitors of
Madhavaram M; Nampally V; Gangadhari S; Palnati MK; Tigulla P
J Recept Signal Transduct Res; 2019 Aug; 39(4):312-320. PubMed ID: 31658859
[TBL] [Abstract][Full Text] [Related]
27. Naphthoquinones isolated from Diospyros anisandra exhibit potent activity against pan-resistant first-line drugs Mycobacterium tuberculosis strains.
Uc-Cachón AH; Borges-Argáez R; Said-Fernández S; Vargas-Villarreal J; González-Salazar F; Méndez-González M; Cáceres-Farfán M; Molina-Salinas GM
Pulm Pharmacol Ther; 2014 Feb; 27(1):114-20. PubMed ID: 23968826
[TBL] [Abstract][Full Text] [Related]
28.
Jagadeb M; Rath SN; Sonawane A
J Biomol Struct Dyn; 2019 Aug; 37(13):3388-3398. PubMed ID: 30132739
[TBL] [Abstract][Full Text] [Related]
29. Structural insight into Mycobacterium tuberculosis maltosyl transferase inhibitors: pharmacophore-based virtual screening, docking, and molecular dynamics simulations.
Sengupta S; Roy D; Bandyopadhyay S
J Biomol Struct Dyn; 2015; 33(12):2655-66. PubMed ID: 25669125
[TBL] [Abstract][Full Text] [Related]
30. Cytochromes P450: novel drug targets in the war against multidrug-resistant Mycobacterium tuberculosis.
Munro AW; McLean KJ; Marshall KR; Warman AJ; Lewis G; Roitel O; Sutcliffe MJ; Kemp CA; Modi S; Scrutton NS; Leys D
Biochem Soc Trans; 2003 Jun; 31(Pt 3):625-30. PubMed ID: 12773169
[TBL] [Abstract][Full Text] [Related]
31. Discovery and development of novel salicylate synthase (MbtI) furanic inhibitors as antitubercular agents.
Chiarelli LR; Mori M; Barlocco D; Beretta G; Gelain A; Pini E; Porcino M; Mori G; Stelitano G; Costantino L; Lapillo M; Bonanni D; Poli G; Tuccinardi T; Villa S; Meneghetti F
Eur J Med Chem; 2018 Jul; 155():754-763. PubMed ID: 29940465
[TBL] [Abstract][Full Text] [Related]
32. Identification of inhibitors against Mycobacterium tuberculosis thiamin phosphate synthase, an important target for the development of anti-TB drugs.
Khare G; Kar R; Tyagi AK
PLoS One; 2011; 6(7):e22441. PubMed ID: 21818324
[TBL] [Abstract][Full Text] [Related]
33. Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
Choi J; Park SJ; Jee JG
Eur J Med Chem; 2015 Dec; 106():157-66. PubMed ID: 26544630
[TBL] [Abstract][Full Text] [Related]
34. Back to the future: a new 'old' lead for tuberculosis.
Wright GD
EMBO Mol Med; 2012 Oct; 4(10):1029-31. PubMed ID: 22987753
[No Abstract] [Full Text] [Related]
35. Natural products as leads for tuberculosis drug development.
Salomon CE; Schmidt LE
Curr Top Med Chem; 2012; 12(7):735-65. PubMed ID: 22283816
[TBL] [Abstract][Full Text] [Related]
36. Discovery of novel and potent InhA direct inhibitors by ensemble docking-based virtual screening and biological assays.
Zhang Q; Han J; Zhu Y; Yu F; Hu X; Tong HHY; Liu H
J Comput Aided Mol Des; 2023 Dec; 37(12):695-706. PubMed ID: 37642861
[TBL] [Abstract][Full Text] [Related]
37. Current Advances in Antitubercular Drug Discovery: Potent Prototypes and New Targets.
Dos Santos Fernandes GF; Jornada DH; de Souza PC; Chin CM; Pavan FR; Dos Santos JL
Curr Med Chem; 2015; 22(27):3133-61. PubMed ID: 26282941
[TBL] [Abstract][Full Text] [Related]
38. Prioritization of natural compounds against mycobacterium tuberculosis 3-dehydroquinate dehydratase: A combined in-silico and in-vitro study.
Lone MY; Athar M; Gupta VK; Jha PC
Biochem Biophys Res Commun; 2017 Sep; 491(4):1105-1111. PubMed ID: 28789944
[TBL] [Abstract][Full Text] [Related]
39. New tuberculostatic agents targeting nucleic acid biosynthesis: drug design using QSAR approaches.
Bueno RV; Braga RC; Segretti ND; Ferreira EI; Trossini GH; Andrade CH
Curr Pharm Des; 2014; 20(27):4474-85. PubMed ID: 24245758
[TBL] [Abstract][Full Text] [Related]
40. Screening of antitubercular compound library identifies novel shikimate kinase inhibitors of Mycobacterium tuberculosis.
Rajput VS; Mehra R; Kumar S; Nargotra A; Singh PP; Khan IA
Appl Microbiol Biotechnol; 2016 Jun; 100(12):5415-26. PubMed ID: 26887318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
